No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds.

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
Daniëlle M E van AssemaB N M van Berckel

Abstract

Decreased blood-brain barrier P-glycoprotein (Pgp) function has been shown in Alzheimer's disease (AD) patients using positron emission tomography (PET) with the radiotracer (R)-[(11)C]verapamil. Decreased Pgp function has also been hypothesized to promote cerebral amyloid angiopathy (CAA) development. Here, we used PET and (R)-[(11)C]verapamil to assess Pgp function in eighteen AD patients, of which six had microbleeds (MBs), presumably reflecting underlying CAA. No differences were found in binding potential and nonspecific volume of distribution of (R)-[(11)C]verapamil between patient groups. These results provide no evidence for additional Pgp dysfunction in AD patients with MBs.

References

Jun 6, 2000·Advanced Drug Delivery Reviews·A H Schinkel
Jan 5, 2001·Cancer Treatment Reviews·J BartE G de Vries
May 16, 2009·Stroke; a Journal of Cerebral Circulation·Eric E Smith, Steven M Greenberg
Oct 22, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Jurgen E M MourikRonald Boellaard
Jun 15, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Nelleke TolboomBart N M van Berckel
Dec 15, 2010·Science·Kwasi G MawuenyegaRandall J Bateman
Jan 25, 2011·Brain : a Journal of Neurology·Charlotte Cordonnier, Wiesje M van der Flier
Nov 29, 2011·Brain : a Journal of Neurology·Daniëlle M E van AssemaBart N M van Berckel
Dec 23, 2011·Annals of Neurology·Anand Viswanathan, Steven M Greenberg

❮ Previous
Next ❯

Citations

Mar 16, 2013·Molecular Neurobiology·Juan M Zolezzi, Nibaldo C Inestrosa
Dec 8, 2015·Biomarkers in Medicine·Sara Shams, Lars-Olof Wahlund
Dec 20, 2014·Neuroscience and Biobehavioral Reviews·Harm J van de HaarWalter H Backes
Jul 17, 2014·Drug Discovery Today. Technologies·Jens P Bankstahl
Jul 9, 2016·Journal of Neurology·T PoliakovaI Zerr
Aug 23, 2016·Neurobiology of Disease·Fernanda MarquesJoana Almeida Palha
Sep 20, 2016·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Amir A SepehryDonna J Lang
Nov 30, 2018·Frontiers in Neurology·Whitney M FreezeCatharina J M Klijn

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Related Papers

Brain : a Journal of Neurology
Daniëlle M E van AssemaB N M van Berckel
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
W VallatT J Kleinig
© 2021 Meta ULC. All rights reserved